Abivax (Euronext Paris and Nasdaq: ABVX) saw its stock surge 63% in Europe and 50% in the United States over four trading days, following the release of positive new data for its late-stage ulcerative colitis (UC) drug candidate obefazimod. The rebound comes less than a month after shares roller-coastered on safety signals associated with the therapy, according to a report by Genetic Engineering News.
The newly disclosed data appeared to reassure investors about the drug's safety and efficacy profile, though specific numerical results from the trial were not detailed in the source. The candidate is being evaluated in a late-stage clinical program for moderate to severe UC, a chronic inflammatory bowel disease affecting millions worldwide.
Regulatory timelines and a potential PDUFA date for obefazimod were not mentioned in the source article. Typically, FDA review follows completion of pivotal Phase 3 trials but no such milestones were confirmed in this report.
For Abivax, a dual-listed biotech with operations in France and the U.S., the stock recovery signals renewed investor confidence after the earlier volatility. The UC treatment market, dominated by expensive biologics and small molecules, represents a multi-billion-dollar opportunity if obefazimod eventually gains approval.
Some investors remain cautious, given the prior safety signals that triggered the initial sell-off. Without detailed efficacy and safety data from the full trial readout, questions about the drug's risk-benefit profile persist.